SIGA Technologies to Host Business Update Call on May 7 After Q1 2024 Results

NEW YORK, May 01, 2024 - SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a company specializing in pharmaceuticals, announced that its management will conduct a webcast and conference call to provide a business update. This event is scheduled for 4:30 P.M. ET on Tuesday, May 7, 2024. The call will feature Diem Nguyen, the Chief Executive Officer, and Daniel Luckshire, the Chief Financial Officer. The live webcast can be accessed on the company's website under the 'Events & Presentations' tab in the Investor Relations section.

Participants are advised to log in approximately 5-10 minutes before the scheduled start time. The call can be accessed by dialing 1-888-886-7786 for domestic participants or 1-416-764-8658 for international participants. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers, using Conference ID: 27772151. The archived webcast will also be accessible on the company's website.

SIGA Technologies, Inc. is a pharmaceutical company in the commercial stage, with a focus on the health security market. Health security includes countermeasures for biological, chemical, radiological, and nuclear threats, as well as vaccines and treatments for emerging infectious diseases. The company's leading product is TPOXX®, also known by its chemical name, tecovirimat, and ST-246®. It is an antiviral medication available in both oral and intravenous formulations, designed to treat smallpox caused by the variola virus.

TPOXX® is a groundbreaking small-molecule drug, and the U.S. maintains a stockpile of it under Project BioShield. The FDA approved the oral formulation of TPOXX for smallpox treatment in 2018, and its IV counterpart received approval in 2022 for the same use. The complete label for both formulations is available on the company's website. Additionally, oral tecovirimat was approved by the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. These approvals extend the use of oral tecovirimat to treat smallpox, monkeypox, cowpox, and complications from vaccinia following smallpox vaccination. The label for these approvals is also available on the company's website.

In September 2018, SIGA Technologies entered into a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This contract supports additional procurement and development for both oral and intravenous formulations of TPOXX.

Orthopoxviruses, the family to which smallpox, mpox, cowpox, and vaccinia belong, continue to pose a significant threat to global health security. Smallpox is a highly contagious and often fatal disease, raising concerns about its potential use as a bioweapon. Mpox, similar to smallpox, causes sporadic human infections, painful lesions, and can be fatal. Recent outbreaks of mpox have been reported in the US, Europe, and Central & West Africa. Given the risk of natural outbreaks or bioweapon use, antivirals and vaccines are critical countermeasures to address these threats.